The Biden administration plans to utilize the Defense Production Act to boost essential medicine manufacturing; a landmark case challenges Texas abortion laws; reports of the BA.2.86 variant of SARS-CoV-2 have nearly tripled in the United States.
In response to a historic surge in drug shortages and the dependence on overseas suppliers for pharmaceutical ingredients, the Biden administration has revealed a comprehensive plan to enhance the domestic production of crucial medicines, according to Axios. Leveraging the Defense Production Act, originally enacted during the Korean War, Biden aims to direct private companies to manufacture essential pharmaceuticals, including insulin, morphine, vaccines, and ventilators. While experts applauded the move as a positive step, they also emphasized the need for additional actions and funding to address the vulnerability of the drug supply chain, highlighting the importance of securing the entire manufacturing process within the United States.
The Texas Supreme Court is set to deliberate on a pivotal case brought by the Center for Reproductive Rights, questioning the harm caused to women dealing with pregnancy complications under the state's restrictive abortion laws, according to NPR. With 22 plaintiffs, including patients and physicians, the lawsuit contends that Texas' narrow medical exceptions fail to adequately protect individuals with complex pregnancies. As the court considers a temporary injunction that could broaden abortion exceptions, the case underscores the broader legal battle over reproductive rights in the state, with potential implications for similar laws across the nation.
CDC data revealed a substantial rise in the prevalence of the BA.2.86 COVID-19 variant in the United States, estimating that nearly 1 in 10 new cases are now attributed to this highly mutated strain, according to CBS News. The Northeast, particularly New York and New Jersey, is experiencing the largest impact, with 13.1% of cases linked to the BA.2.86 variant. Despite the surge, the CDC asserts that, for now, the variant does not appear to be driving significant increases in infections or hospitalizations, while experts monitor the situation closely amid a renewed rise in COVID-19 indicators nationwide.
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Senate Finance Committee has introduced bipartisan legislation that proposes using Medicaid and Medicare programs to help prevent and reduce generic drug shortages; US indicators for COVID-19, flu, and respiratory syncytial virus (RSV) declined further last week; findings from a recent study reveal growing disparities in child death rates across racial and ethnic groups.
Read More